Free Trial
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Chemomab Therapeutics logo
$1.16 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 +0.01 (+0.43%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Key Stats

Today's Range
$1.15
$1.22
50-Day Range
$1.16
$1.42
52-Week Range
$0.87
$2.55
Volume
110,619 shs
Average Volume
219,501 shs
Market Capitalization
$21.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Chemomab Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

CMMB MarketRank™: 

Chemomab Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 475th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Chemomab Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chemomab Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chemomab Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chemomab Therapeutics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Chemomab Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.04% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 138.18%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Chemomab Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Chemomab Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.04% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 138.18%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Chemomab Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Chemomab Therapeutics' insider trading history.
Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMMB Stock News Headlines

Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
Chemomab Hikes on Q1 Figures
See More Headlines

CMMB Stock Analysis - Frequently Asked Questions

Chemomab Therapeutics' stock was trading at $1.81 at the beginning of the year. Since then, CMMB shares have decreased by 35.9% and is now trading at $1.16.
View the best growth stocks for 2025 here
.

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) released its earnings results on Thursday, May, 15th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06.

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

Company Calendar

Last Earnings
5/15/2025
Today
7/01/2025
Next Earnings (Estimated)
8/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMMB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+611.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.94 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
1.66

Miscellaneous

Free Float
16,611,000
Market Cap
$22.54 million
Optionable
Not Optionable
Beta
0.48
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:CMMB) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners